Beam Therapeutics vs Macrogenics
Beam Therapeutics and Macrogenics are similar in size: $140m and $150m of revenue in their latest fiscal years. Beam Therapeutics grew faster (120.0% against -0.3%). Macrogenics kept more of each dollar of sales as profit: a net margin of -49.9% against -57.2%. Beam Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Beam TherapeuticsBEAM, 2025 | MacrogenicsMGNX, 2025 |
|---|---|---|
| Revenue | $140m | $150m |
| Revenue growth | 120.0% | -0.3% |
| Net income | −$80.0m | −$74.6m |
| Operating margin | -274.6% | -48.7% |
| Net margin | -57.2% | -49.9% |
| Return on equity | -8.1% | -86.9% |
| Free cash flow | −$360m | −$83.0m |
| Cash | $295m | $57.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 511 | 293 |
| Market value | $2.74bn | $149m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 29 (Weak) |
| Insider trades, 12 months | 0 buys, 31 sales | 0 buys, 1 sales |